Selected References:

• Aagaard J, et al. 1991. Prostatic tissue levels of ofloxacin. Urology, 38:380-382.
• Cahill JB Jr, et al. 2005. Levofloxacin secretion in breast milk: a case report. Pharmacotherapy, 25:116-118.
• Caplin Sterile Limited. 2024. Ofloxacin product label. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo. Accessed June 20 2024.
• Danisovicova A, et al. 1994. Magnetic resonance imaging in children receiving quinolones: no evidence of quinolone-induced arthropathy. A multicenter survey. Chemotherapy, 40:209-214.
• Drobac PC, et al. 2005. Treatment of multidrug-resistant tuberculosis during pregnancy: long-term follow-up of 6 children with intrauterine exposure to second-line agents. Clin Infect Dis, 40:1689-1692.
• Erhart B, et al. 1998. Ofloxacin: the next generation of antibiotic in sperm and embryo cultures for assisted reproductive technologies. Fertil Steril, 69(2):246-251.
• Falagas ME, et al. 2007. Arrhythmias associated with fluoroquinolone therapy. Int J Antimicrob Agents, 29(4):374-379.
• Giamarellou H, et al. 1989. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med, 87(5A):49S-51S.
• Loebstein R, et al. 1998. Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study. Antimicrob Agents Chemother, 42:1336-1339.
• Muanda Ft, et al. 2017. Use of antibiotics during pregnancy and the risk of major congenital malformations: a population based cohort study. Br J Clin Pharmacol, 83:2557-2571.
• Naber KG, et al. 1993. Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection, 21(2):98-100.
• Nivagen Pharmaceuticals Inc. 2023. Ofloxacin product label. Available at: https://dailymed.nlm.nih.gov/dailymed/drugInfo. Accessed June 20 2024.
• Padberg S, et al. 2014. Observational cohort study of pregnancy outcomes after first-trimester exposure to fluoroquinolones. Antimicrob Agents Chemother, 58(8):4392-4398.
• Peled Y, et al. 1991. Ofloxacin during the second trimester of pregnancy. DICP, 25(11):1181-1182.
• Schaefer C, et al. 1996. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS). Eur J Obstet Gynecol Reprod Biol, 69(2):83-89.
• Schramm P. 1986. Ofloxacin: concentration in human ejaculate and influence on sperm motility. Infection, 14 Suppl 4:S274-S275.
• Shao S, et al. 2023. Association between antibiotic exposure and the risk of infertility in women of childbearing age: a case-control study. Ecotoxicol Environ Saf, 249: 114414.
• Shin YJ, et al. 2018. Pregnancy outcomes in women reporting exposure to ofloxacin in early pregnancy. J Obstet Gynaecol, 38(6):807-812.
• Wilton LV, et al. 1998. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. British J Obstet Gynecol, 105:882-889.
• Yamaguchi H, et al. 2007. Post-marketing surveillance of the safety of levofloxacin in Japan. Chemotherapy, 53(2):85-103.

Selected References:

• Bhoj E, et al. 2013. Late-onset partial complex seizures secondary to cortical dysplasia in a patient with maternal vitamin K deficient embryopathy: comments on the article by Toriello et al. [2013] and first report of the natural history. Am J Med Genet A. 161(9):2396-2398.
• Dickson RC, et al. 1994. Antenatal vitamin K therapy of the low-birth-weight infant. Am J Obstet Gynecol 170:85-89.
• Eventov-Friedman S, et al. 2009. Third trimester fetal intracranial hemorrhage owing to vitamin K deficiency associated with hyperemesis gravidarum. J Pediatr Hematol Oncol. 31(12):985-988.
• Goto T, et al. 2018. A rare case of fetal extensive intracranial hemorrhage and whole-cerebral hypoplasia due to latent maternal vitamin K deficiency. J Neonatal Perinatal Med 11(2): 191-194.
• Kawamura Y, et al. 2008. Vitamin K deficiency in hyperemesis gravidarum as a potential cause of fetal intracranial hemorrhage and hydrocephalus. Prenat Diagn. 28(1):59-61.
• Kazzi NJ, et al. 1989. Maternal administration of vitamin K does not improve the coagulation profile of preterm infants. Pediatrics 84:1045-1050.
• Klebanoff MA, et al. 1993. The risk of childhood cancer after neonatal exposure to vitamin K. N Engl J Med 329: 905-908.
• Lee S, et al. 2022. Fetal intracranial hemorrhage and maternal vitamin K deficiency induced by total parenteral nutrition: A case report. Medicine (Baltimore). 101(1):e28434.
• Morales WJ, et al. 1988. The use of antenatal vitamin K in the prevention of early neonatal intraventricular hemorrhage. Am J Obstet Gynecol 159:774-779.
• Njisten K, et al. 2022. Hyperemesis gravidarum and vitamin K deficiency: a systematic review. Br J Nutr 128(1):30-42.
• Pomerance JJ, et al. 1987. Maternally administered antenatal vitamin K1: effects on neonatal prothrombin activity, partial thromboplastin time, and intraventricular hemorrhage. Obstet Gynecol 70:235-241.
• Robinson JN, et al. 1998. Coagulopathy secondary to vitamin K deficiency in hyperemesis gravidarum. Obstet Gynecol 92:673-675.
• Roman E, et al. 2002. Vitamin K and childhood cancer: analysis of individual patient data from six case-control studies. Br J Cancer 86:63-69.
• Sotodate G, et al. 2019. Fetal intracranial hemorrhage due to maternal subclinical vitamin K deficiency associated with long-term eating disorder. J Obstet Gynaecol Res. 2019 Feb;45(2):461-465.
• Toriello HV, et al. 2013. Maternal vitamin K deficient embryopathy: association with hyperemesis gravidarum and Crohn disease. Am J Med Genet A. 161A(3):417-429.
• Yasuda K, et al. 2023. Intrauterine fetal death due to fetal intracranial hemorrhage associated with maternal vitamin K deficiency: A case report. Case Rep Womens Health 40: e00566.

Selected References:

• Castilletti, et al. 2024. Replication-competent Oropouche virus in semen of traveler returning to Italy from Cuba, 2024. Emerging infectious diseases, 30(12), 10.3201/eid3012.241470.
• Centers for Disease Control and Prevention. 2024. Complications of Oropouche and Pregnancy. Available at URL: https://www.cdc.gov/oropouche/health-effects/pregnancy.html [Accessed October 25, 2024].
• Centers for Disease Control and Prevention. 2024. Interim Clinical Considerations for Pregnant Women with Confirmed or Probable Oropouche Virus Disease. Available at URL: https://www.cdc.gov/oropouche/hcp/clinical-care/pregnancy.html [Accessed October 25, 2024].
• Centers for Disease Control and Prevention. 2024. Interim Guidance for Evaluating and Managing Infants Born to Pregnant Women with Confirmed or Probable Oropouche Virus Disease. Available at URL: https://www.cdc.gov/oropouche/hcp/clinical-care/infants.html [Accessed October 25, 2024].
• das Neves Martins, et al. 2024. Newborns with microcephaly in Brazil and potential vertical transmission of Oropouche virus: a case series. The Lancet. Infectious diseases, S1473-3099(24)00617-0.
• Garcia Filho C, et al. 2024. A case of vertical transmission of Oropouche Virus in Brazil. N Engl J Med, 10.1056/NEJMc2412812.
• Martins-Filho, et al. 2024. Oropouche fever: reports of vertical transmission and deaths in Brazil. The Lancet. Infectious diseases, S1473-3099(24)00557-7.
• Pan American Health Organization, 2024. Epidemiological Update: Oropouche in the Americas Region, 15 October 2024. Available at URL: https://www.paho.org/en/documents/epidemiological-update-oropouche-americas-region-15-october-2024 [Accessed November 8, 2024].

Selected References:

• American College of Obstetricians and Gynecologists (ACOG). 2017. Reaffirmed October 2021. Committee Opinion No. 711: Opioid use and opioid use disorder in pregnancy. Obstet Gynecol, 130:e81-e94. 
• American Society of Addiction Medicine. 2017. Clinical Recommendations: Opioid Use and Opioid Use Disorder in Pregnancy. A Joint Opinion of the ACOG’s Committee on Obstetric Practice and ASAM. Available at https://www.asam.org/quality-care/clinical-recommendations/OUD-in-Pregnancy [retrieved February 2025]. 
• Anderson JM, et al. 2020. Prenatal exposure to methadone or buprenorphine and long-term outcomes: a meta-analysis. Early Human Development, 143:104997. 
• Asad M, et al. 2024. Reviewing the impact of maternal opioid use disorder on fetal development and long-term pediatric health outcomes. Cureus, 16(10):e72192. 
• Aslaksen AK, et al. 2024. Children had increased risks of impaired motor and visual-motor skills after prenatal exposure to opioid maintenance therapy. Acta Paediatr, 113(6):1331-1339. 
• Aslaksen AK, et al. 2024. Visual function in Norwegian children aged 5-13 years with prenatal exposure to opioid maintenance therapy: a case-control study. Acta Ophthalmol, 102(4):409-420. 
• Austin A, et al. 2021. Prenatal use of medication for opioid use disorder and other prescription opioids in cases of neonatal opioid withdrawal syndrome: North Carolina Medicaid, 2016-2018. Am J Public Health, 111(9):1682-1685. 
• Bello JK, et al. 2024. Pregnancy rates among women treated with medication for opioid use disorder. J Gen Intern Med, 39(8):1342-1348. 
• Caritis SN, Venkataramanan R. A pharmacologic evaluation of buprenorphine in pregnancy and the postpartum period. J Addict Med, 19(2):129-134.  
• Chao CR, et al. 2023. Effects of medications for opioid use disorder (MOUD) on fetal brain and cranial measurements. Neurotoxicol Teratol, 97:107177.  
• Conradt E, et al. 2019. Prenatal opioid exposure: Neurodevelopmental consequences and future research priorities. Pediatrics, 144(3):e20190128. 
• Coulson C, et al. 2021. Association of maternal buprenorphine or methadone dose with fetal growth indices and neonatal abstinence syndrome. Am J Perinatol, 38(01):028-036. 
• Dean MP, et al. 2025. Increased prevalence of skeletal anomalies on ultrasound evaluation of buprenorphine-exposed human fetuses. South Med J, 118(1):39-44. 
• Dorey A, et al. 2019. Possible buprenorphine toxicity in a breastfeeding neonate. Clin Toxicol, 57:889-890. 
• Gawronski KM, et al. 2014. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. SAGE Open Medicine, 2:2050312114530282.  
• Giovannini E, et al. 2024. Fetal and infant effects of maternal opioid use during pregnancy: a literature review including clinical, toxicological, pharmacogenomic, and epigenetic aspects for forensic evaluation. Children (Basel), 11(3):278. 
• Handal M, et al. 2019. Prenatal exposure to opioid maintenance treatment and neonatal outcomes: nationwide registry studies from the Czech Republic and Norway. Pharmacol Res Perspect, 7(5):e00501. 
• Harris E. 2023. Buprenorphine treatment may be safer than methadone during pregnancy. JAMA, 331(7):555. 
• Hasan M, et al. 2024. Neurodevelopmental outcomes in children prenatally exposed to opioid maintenance treatment: a population-based study. Pharmacotherapy, 44(10):770-781. 
• Hubbell A, et al. 2024. Extended-release buprenorphine in pregnancy. Am J Addict, 33(3):354-356. 
• Ito, S. 2018. Opioids in breast milk: Pharmacokinetic principles and clinical implications. J Clin Pharmacol, 58 Suppl 10:S151-S163. 
• Jansson LM, et al. 2017. Maternal buprenorphine treatment and infant outcome. Drug Alcohol Depen, 180:56-61. 
• Jansson LM, et al. 2016. Maternal buprenorphine maintenance and lactation. J Hum Lact, 32:675-81. 
• Jones HE, et al. 2012. Buprenorphine treatment of opioid-dependent pregnant women: a comprehensive review. Addiction 107, (Suppl. 1):5–27. 
• Jones JD, et al. 2012. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend, 125(1-2):8–18. 
• Hemmati Z, et al. 2022. Ophthalmic outcomes in children exposed to opioid maintenance treatment in utero: a systematic review and meta-analysis. Neurosci Biobehav Rev, 136:104601. 
• Jansson LM, et al. 2024. Buprenorphine-naloxone maintenance and lactation. J Hum Lact, 40(1):113-119. 
• Jarlenski M, et al. 2024. Association between buprenorphine dose and outcomes among pregnant persons with opioid use disorder. Am J Obstet Gynecol, S0002-9378(24)01178-5. 
• Kacinko S, et al. 2008. Correlations of maternal buprenorphine dose, buprenorphine, and metabolite concentrations in meconium with neonatal outcomes. Clin Pharmacol Ther, 84(5):604-612. 
• Kallenbach K, et al. 2012. Predicting treatment for neonatal abstinence syndrome in infants born to women maintained on opioid agonist medication. Addiction 107, (Suppl. 1):45-52. 
• Kanervo, MM, et al. 2023. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. Acta Obstet Gynecol Scand, 102:313-322. 
• Kanervo M, et al. 2024. Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth. Acta Paediatr, 113(7):1579-1591. 
• Kanervo M, et al. 2024. Extended-release versus oral buprenorphine as opioid maintenance treatment during pregnancy-maternal and neonatal outcomes. Eur J Obstet Gynecol Reprod Biol, 297:106-110. 
• Kinsella M, et al. 2022. Buprenorphine compared with methadone in pregnancy: a systematic review and meta-analysis. Subst Use Misuse, 57(9):1400-1416.  
• Knittel AK, et al. 2023. Neonatal outcomes after medications for opioid use disorder during pregnancy in a state women’s prison facility, 2016-2019. J Addict Med, 17(5):587-591. 
• Kocherlakota P. 2014. Neonatal bstinence syndrome. Pediatrics, 134(2):e547-e561. 
• Krans EE, et al. 2021. Outcomes associated with the use of medications for opioid use disorder during pregnancy. Addiction, 116(12):3504-3514. 
• Kumar N, et al. 2021. Impact of opioid maintenance treatment during pregnancy on neonatal birth weight and head circumference. J Neonatal Perinatal Med, 14(4):475-484.  
• Kushnir A, et al. 2023. Neonatal abstinence syndrome in infants with prenatal exposure to methadone versus buprenorphine. Children (Basel), 10(6):1030. 
• Mallinson DC, et al. 2024. Maternal opioid use disorder and infant mortality in Wisconsin, United States, 2010-2018. Prev Med, 181:107914. 
• Marc B, et al. 2025. Is buprenorphine maternal dose associated with neonatal opioid withdrawal syndrome severity? Am J Addict, 34(1):15-20. 
• Nelson LF, et al. 2020. Cognitive outcomes of young children after prenatal exposure to medications for opioid use disorder: a systematic review and meta-analysis. JAMA Netw Open,3(3):e201195. 
• Reece-Stremtan S, Marinelli KA. 2015. ABM Clinical Protocol #21: Guidelines for breastfeeding and substance use or substance use disorder, Revised 2015. Breastfeed Med, 10(3):135-141. 
• Ordean A, Tubman-Broeren M. 2023. Safety and efficacy of buprenorphine-naloxone in pregnancy: a systematic review of the literature. Pathophysiology, 30(1):27-36. 
• Patel N, et al. 2024. Weaning buprenorphine in pregnant patients. J Matern Fetal Neonatal Med, 37(1):2337711. 
• Patel NB, Parilla BV. 2024. Buprenorphine induction using microdosing for the management of opioid use disorder in pregnancy. AJP Rep, 14(1):e88-e90.  
• Schuckit MA. 2016. Treatment of opioid-use disorders.  N Engl J.Med, 375:357–68. 
• Shah D, et al. 2025. Outpatient tapering of buprenorphine in opioid use disorder pregnancies may improve neonatal outcomes. J Perinatol, doi: 10.1038/s41372-025-02211-6. 
• Smith D, et al. 2024. Evaluating the effect of maternal opioid maintenance dose on the NOWS-COS outcome criteria: a pilot study. Clin Pediatr (Phila), 63(12):1670-1677. 
• Soyka M, 2013. Buprenorphine use in pregnant opioid users: a critical review. CNS Drugs, 27(8):653-662. 
• Staszewski CL, et al. 2020. Comparison of buprenorphine and methadone in the management of maternal opioid use disorder in full term pregnancies. J Perinat Med Sep, 25;48(7):677-680. 
• Straub L, et al. 2024. Comparative safety of in utero exposure to buprenorphine combined with naloxone vs buprenorphine alone. JAMA, 332(10):805-816. 
• Suarez EA, et al. 2022. Buprenorphine versus methadone for opioid use disorder in pregnancy. N Engl J Med, 387(22):2033-2044. 
• Suarez EA, et al. 2024. First trimester use of buprenorphine or methadone and the risk of congenital malformations. JAMA Intern Med, 184(3):242-251. 
• Sundelin-Wahlsten V, Sarman I. 2013. Neurobehavioural development of preschool-age children born to addicted mothers given opiate maintenance treatment with buprenorphine during pregnancy. Acta Paediat, 102(5): 544-549. 
• Wiegand SL, et al. 2015. Buprenorphine and naloxone compared with methadone treatment in pregnancy. Obstet Gynecol, 125(2):363-368. 
• Wouldes TA, Lester BM. 2023. Opioid, methamphetamine, and polysubstance use: perinatal outcomes for the mother and infant. Front Pediatr, 11:1305508. 

Selected References:

• Bohlke K, et al. 2003. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? Obstet Gynecol; 102(5 Pt 1):970-7.
• Centers for Disease Control and Prevention. 1996. Prevention of varicella. MMWR; 45(RR-11);1-36.
• Centers for Disease Control and Prevention. 2013. Updated Recommendations for Use of VariZIG — United States, 2013. MMWR. 62(28):574-576.
• Centers for Disease Control and Prevention. Guidelines for vaccinating pregnant women (2012, updated 2016). https://www.cdc.gov/vaccines-pregnancy/hcp/vaccination-guidelines/index.html
• Centers for Disease Control and Prevention. 2022. Pregnancy guidelines and recommendations by vaccine. Centers for Disease Control and Prevention.
• Chan DYL, et al. 2017. Human varicella zoster virus is not present in the semen of a man affected by chickenpox during the in vitro fertilisation of is wife. Andrologia 49(10):e12822.
• Cohen A, et al. Congenital varicella syndrome: the evidence for secondary prevention with varicella-zoster immune globulin. CMAJ:183(2):204-208.
• Committee on Infectious Diseases, American Academy of Pediatrics. 1995. Recommendations for the use of live attenuated varicella vaccine. Pediatrics; 95:791-796.
• Frederick IB, et al. 1986. Excretion of varicella-herpes zoster in breast milk. Am J Obstet Gynecol; 154:1116-1117.
• Garcia-Loygorri MC, et al. LA LECHE MATERNA COMO VEHÍCULO DE TRANSMISIÓN DE VIRUS [BREAST MILK AS A VEHICLE OF TRANSMISSION OF VIRUS]. Nutr Hosp.;32(1):4-10. Spanish.
• Gruslin A, et al; SOGC. 2008. Immunization in pregnancy: No. 220, December 2008. Int J Gynaecol Obstet; 105(2):187-191.
• Hayward K, et al. 2018. Management of herpes zoster (shingles) during pregnancy. J Obstet Gynaecol 38(7):887-894.
• Kimberlin DW, et al. 2018 Report of the Committee on Infectious Diseases. 31st ed. Elk Grove Village, IL: American Academy of Pediatrics. 883.
• Losa, L., et al. (2024). Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression. Vaccines, 12(5), 527. https://doi.org/10.3390/vaccines12050527
• Marin M, et al. 2013. Closure of Varicella-Zoster Virus-Containing Vaccines Pregnancy Registry – United States. MMWR 63(33);732-733.
• National Center for Immunization and Respiratory Diseases. 2011. General recommendations on immunization — recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60(2):1-64. Erratum in: MMWR Recomm Rep 2011;60:993.
• Psarris A, et.al. 2019. Immunizations during pregnancy: How, when and why.  Eur J Obstet Gynecol Reprod Biol Sep;240:29-35.
• Willis ED. et al. 2022. Merck/Centers for Disease Control and Prevention Varicella Vaccine Pregnancy Registry: 19-Year Summary of Data From Inception Through Closure, 1995-2013. J Infect Dis. 226(Suppl 4):S441-S449.
• Woodward M, et. al. 2019. Varicella virus vaccine live: A 22-year review of postmarketing safety data. Open Forum Infect Dis 6(8):ofz295.